New approach for treating idiopathic pulmonary fibrosis

June 8, 2015, Helmholtz Association of German Research Centres

Researchers at Helmholtz Zentrum München, in collaboration with an international team, have identified a potential novel drug target for idiopathic pulmonary fibrosis, a dangerous chronic lung disease. They elucidated a new mechanism of fibrosis formation that plays an important role in the pathogenesis of the disease. These findings have now been published in the leading scientific journal American Journal of Respiratory and Critical Care Medicine.

Idiopathic pulmonary fibrosis (IPF) is a for which as yet no causal therapy exists. It is, however, known that the lung interstitium – the connective tissue between the air sacs in the lower part of the lung – is affected. There scar tissue consisting mainly of collagen accumulates, thus reducing lung elasticity and gradually impairing lung function. Patients with IPF have an extremely poor prognosis; on average they survive only two or three years after the diagnosis has been made.

Analysis of patient data

Prof. Dr. Oliver Eickelberg and Dr. Claudia Staab-Weijnitz of the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum München and their colleagues at LMU University Hospital in Munich and Yale University School of Medicine have now discovered a new therapeutic target for IPF. The main focus of their research was to identify causative mechanisms involved in the disease. The researchers analyzed microarray data of samples from German patients and from an IPF cohort of the Lung Tissue Research Consortium in the U.S.

The analysis revealed elevated levels of the protein FKBP10 in the lungs of IPF patients. The researchers hypothesized that if the production or activity of the protein could be inhibited, this might lead to a new therapeutic approach. Further experiments confirmed that knockdown of this protein in IPF fibroblasts diminished the collagen synthesis. "Thus, FKBP10 represents a potential new target molecule for the individualized therapy of IPF," said Claudia Staab-Weijnitz. "In the future, these results could also lead to new therapeutic options for the treatment of other fibrotic diseases."

New ways to understand the disease cause

Eickelberg has made the study of IPF one of his key priority research areas. Together with his team of researchers, he is studying the pathogenic mechanisms with the aim to develop causal therapies – and thus one day to actually cure IPF. In the short term, however, the main focus is on delaying the progression of the disease and alleviating the symptoms. "My foremost objective is to help develop an effective treatment that will completely halt the progression of IPF in the patient," said Eickelberg. "These approaches are best developed in international networks. This cooperative project is a direct result of the research stay of Professor Kaminski (Yale) at the CPC through the support of a Helmholtz International Fellow Award (HIFA)."

"With our translational approach," said Eickelberg, "we want to help alleviate the suffering of patients with ." In the case of IPF, the researchers now want to establish a drug screening assay and begin clinical trials with an FKBP10 inhibitor, an agent to inhibit the production or activity of the FKBP10 protein.

Explore further: Promising new target may treat pulmonary fibrosis

More information: "FK506-binding Protein 10 is a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis." Am J Respir Crit Care Med. 2015 Jun 3. www.ncbi.nlm.nih.gov/pubmed/26039104

Related Stories

Promising new target may treat pulmonary fibrosis

March 18, 2015
By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA), along with colleagues in Mexico and Canada, have identified ...

Newly identified biomarkers help predict outcome in idiopathic pulmonary fibrosis

October 2, 2013
A Yale-led study has identified a gene expression profile that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF). The study appears in Science ...

Idiopathic pulmonary fibrosis cases linked with asbestos exposure

September 9, 2014
A proportion of idiopathic pulmonary fibrosis (IPF) cases may be linked with asbestos exposure, according to the results of a new study. If confirmed, the findings would mean that current treatment strategies need to be altered ...

Reversing the effects of pulmonary fibrosis

September 22, 2014
Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

Finding cellular causes of lung-hardening disease

September 17, 2013
(Medical Xpress)—Idiopathic Pulmonary Fibrosis, or IPF, is an incurable lung disease that, over time, turns healthy lung tissue into inflexible scar tissue – hardening the lungs and eventually causing respiratory distress ...

HRCT scans can identify deadly lung disease

February 17, 2014
People who have suspected idiopathic pulmonary fibrosis (IPF) without typical patterns on high resolution computed tomography scans could in future be spared the substantial risks of lung biopsy and be given a confident diagnosis ...

Recommended for you

Beware of getting a tattoo if your immune system isn't up to scratch, doctors warn

June 18, 2018
Getting a tattoo may have some unexpected complications if your immune system isn't up to scratch, warn doctors in the journal BMJ Case Reports.

Recent clinical trial finds tamsulosin not effective in kidney stone passage

June 18, 2018
The latest research into finding medications to aid the passage of ureteral or kidney stones has shown that tamsulosin is not effective for patients across the board. Previously approved to help men experiencing enlarged ...

Research finds new way to determine protection of Men B vaccine against different strains

June 18, 2018
Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero, against different strains that cause meningococcal meningitis ...

Novel molecular target to prevent scarring of the lung blood vessels identified

June 13, 2018
Pulmonary arterial hypertension, a severe form of cardiopulmonary disease in which the arteries that transport blood from the heart to the lungs become thickened, constricted, and scarred, is a disease for which there is ...

Lineage of TB traced and compared to early human migration

June 13, 2018
A team of researchers from the University of Wisconsin, the University of Iowa and the Norwegian Institute of Public Health has carried out genetic studies of tuberculosis to learn more about its lineage and to compare it ...

Fast-acting cholera vaccine could curb outbreaks

June 13, 2018
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest. The rapid protection offered by this designer vaccine may one day limit the spread of cholera outbreaks, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.